Accelerating Drug Development: Using EPSA for High-Throughput Permeability Studies

The continuing rise of Mid-Molecule therapeutics, particularly peptide and oligonucleotide therapies, requires a reexamination of important tools to drug development and design. Traditional criteria, like Lipinski's Rule of 5, and the associated theoretical predictions used to assess oral bioavailability of drug candidates struggle to accurately predict log P and permeability of these larger molecules. 

In this webinar we will discuss the origin and evolution of EPSA as an experimental method to assess lipid bilayer permeability and to inform drug design of the presence and relative level of intramolecular hydrogen bonding. Join us to learn how a sub-7 minute SFC-MS/MS method can streamline the drug candidate funnel and complement PAMPA, CaCO2 / RRCK, and other common permeability assays. Hardware for high-throughput demand, data tools for compliance, and custom reporting create a workflow that can integrate EPSA into your drug development process.

Who should attend: 

Pharmaceutical and Biopharmaceutical Chemists and Laboratory Managers working in areas including Medicinal Chemistry, Drug Candidate Screening, ADME, DMPK, and CROs focusing on therapeutic uptake and bioavailability. 

Learning Objectives: 

• Learn how EPSA provides rapid experimental permeability data for "beyond Ro5" drug candidates
• Understand how EPSA has evolved and expanded to increase throughput
• Discover how Shimadzu SFC and SFC-MS solutions provide easy implementation of EPSA

Speaker: Stephen Kurzyniec (Sr. Market Manager - Pharma/Biopharma, Shimadzu Scientific Instruments)

Stephen holds degrees in biochemistry, cell biology and business administration. He has spent over 20 years in pharmaceutical R&D at both Pfizer and Lundbeck supporting various disease area programs (Cardiovascular, Neurogenerative, Cancer, and therapeutic Vaccines) with both small and large molecule therapies. He has extensive experience in applying a range analytical tools such as LC, LC-MS/MS, HRMS, MALDI, and CE-MS. While previously holding the Pharma/Biopharma Business Development Team Leader and Mass Spec Technical Support Scientist positions, Stephen currently serves as the Shimadzu Sr. Market Manager for Pharma/Biopharma, North America.

Speaker: Brian Domanski (Sr. Strategic Collaboration Scientist, Shimadzu Scientific Instruments)

Brian has over 15 years working to provide solutions for Pharma and Biopharma, with expertise in LC, SFC, LC-MS, and SFC-MS, as well as experience with gas chromatography, molecular spectroscopy, and elemental spectroscopy. His focus also includes scalable Informatics and Data Integrity solutions.